Abvc Biopharma (ABVC) Convertible Debt (2018 - 2024)

Abvc Biopharma (ABVC) has reported Convertible Debt for 5 consecutive years, with $872336.0 the latest figure, recorded in Q1 2024.

• For the quarter ending Q1 2024, Convertible Debt fell 72.8% year-over-year to $872336.0; the trailing twelve-month figure through Mar 2024 stood at $872336.0 (down 72.8% YoY), and the FY2023 full-year result was $886522.0, changed N/A from the prior year.
• Convertible Debt retreated to $872336.0 in Q1 2024 per ABVC's latest filing, from $886522.0 in the prior quarter.
• Across five years, Convertible Debt topped out at $3.3 million in Q2 2023 and bottomed at $872336.0 in Q1 2024.
• Historically, Convertible Debt has averaged $2.2 million across 4 years, with a median of $2.5 million in 2020.
• The widest YoY moves for Convertible Debt: up 72.8% in 2024, down 72.8% in 2024.
• Over 4 years, Convertible Debt stood at $2.5 million in 2020, then changed by 0.0% to $2.5 million in 2021, then tumbled by 64.54% to $886522.0 in 2023, then declined by 1.6% to $872336.0 in 2024.
• According to Business Quant data, Convertible Debt over the past three periods registered $872336.0, $886522.0, and $1.7 million for Q1 2024, Q4 2023, and Q3 2023 respectively.